BRIEF-Biofrontera Achieves Key Milestone In Phase 3 Study Of Ameluz-PDT In Treatment Of sBCC
ReutersJan 8, 2025 4:25 PM
Jan 8 (Reuters) - Biofrontera Inc BFRI.O:
BIOFRONTERA INC. ANNOUNCES ACHIEVEMENT OF KEY MILESTONE IN PHASE 3 STUDY OF AMELUZ®-PHOTODYNAMIC THERAPY (PDT) IN THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
BIOFRONTERA INC - FOLLOW-UP DATA TO BE INCLUDED IN FDA SUBMISSION EXPECTED Q3 2025
Source text: ID:nGNX3C1kk7
Further company coverage: BFRI.O
(((( Reuters.Briefs@thomsonreuters.com ;));))
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
What Should Stock Investors Watch in Friday’s US Jobs Report?
TradingKey - At this point in time, the stock market is obsessing over how much the US Federal Reserve (Fed) will cut interest rates in 2025.TradingKey
12 hours ago
Nvidia CEO’s Remarks Hit Quantum Computing Stocks
TradingKey - Nvidia CEO Jensen Huang’s remarks on Wednesday about the technology hit stocks in the quantum computing sector. He predicted it could take decades for the technology to see widespread adoption, leading to declines in the shares of IonQ, Rigetti Computing, D-Wave Quantum, and Quantum ComTradingKey
14 hours ago
Why Did The S&P 500 And Nasdaq Composite Just Fall Over 1%?
TradingKey - The year 2025 started off on a pretty solid footing for investors with the key indices in the US – the S&P 500 Index and the tech-focused Nasdaq Composite Index – both posting gains in the first few days of trading. That followed on from some huge double-digit gains for 2023 and 2024.TradingKey
Wed, Jan 8
